Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Azitra Reports Preclinical Data Of ATR-12 And Clinical Design On Netherton Syndrome At ASGCT Annual Meeting

Author: Benzinga Newsdesk | May 10, 2024 08:04am

ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndrome
Topical application of ATR-12 to ex vivo human skin results in superior LEKTI delivery compared to topical LEKTI application
ATR-12 reduces IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome
- Safe and well tolerated in minipigs

Posted In: AZTR